FierceBiotech 2026年5月31日 ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%
FierceBiotech 2026年5月30日 In next-gen IO race in NSCLC, BioNTech/BMS and Pfizer are divided on overall survival approach
FierceBiotech 2026年5月30日 ASCO: Gilead touts ADC ovarian cancer data as proof Tubulis buyout was ‘a good deal’
FierceBiotech 2026年5月29日 Legend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform
FierceBiotech 2026年5月29日 AstraZeneca, after phase 3 miss, posts subgroup data behind pitch for rare disease approval
FierceBiotech 2026年5月29日 Agios’ next-gen PK drug fails blood cancer study but sickle cell disease ambitions remain undimmed
FierceBiotech 2026年5月29日 ASCO: BMS’ CELMoD drug doubles PFS in ‘incredibly exciting’ ph. 3 myeloma study
FierceBiotech 2026年5月29日 ASCO: Lilly debuts ‘strong’ bladder cancer data for potential Padcev challenger
FierceBiotech 2026年5月29日 Gilead scraps lead arthritis drug from $405M MiroBio buyout in latest blow to BTLA agonist field
FierceBiotech 2026年5月29日 Pfizer pens $10B, 12-drug deal with Innovent in broad bet on Chinese cancer med innovation
FierceBiotech 2026年5月28日 Icon ends internal accounting investigation, finds it overstated revenue in prior years
FierceBiotech 2026年5月28日 FDA extends Beren’s rare disease review after info request, further stretching saga
FierceBiotech 2026年5月28日 Human Longevity launches newco, teams with Insilico for AI-powered longevity research
FierceBiotech 2026年5月28日 Novartis ‘always looking’ for further ways to shuttle drugs to brain despite run of recent deals
FierceBiotech 2026年5月28日 GSK’s hepatitis B drug cures one-fifth of patients in ‘major step’ for pervasive disease